{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T21:34:12Z","timestamp":1779917652510,"version":"3.53.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T00:00:00Z","timestamp":1677456000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T00:00:00Z","timestamp":1677456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100012173","name":"China-Japan Friendship Hospital","doi-asserted-by":"publisher","award":["ZRJY2021-QM14"],"award-info":[{"award-number":["ZRJY2021-QM14"]}],"id":[{"id":"10.13039\/501100012173","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National High Level Hospital Clinical Research Funding","award":["2022-NHLHCRF-LX-02"],"award-info":[{"award-number":["2022-NHLHCRF-LX-02"]}]},{"name":"Capital\u2019s Funds for Health Improvement and Research","award":["2020-4-40610"],"award-info":[{"award-number":["2020-4-40610"]}]},{"name":"National Regional Traditional Chinese Medicine (Specialty) Treatment Center Project","award":["2019-ZX-006"],"award-info":[{"award-number":["2019-ZX-006"]}]},{"name":"National Key Clinical Specialty Building Project","award":["2011-ZDZK-001"],"award-info":[{"award-number":["2011-ZDZK-001"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s10067-023-06540-9","type":"journal-article","created":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T18:02:52Z","timestamp":1677520972000},"page":"1999-2011","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Knowledge mapping of biological disease-modifying anti-rheumatic drugs for axial spondyloarthritis: a bibliometric study"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3203-696X","authenticated-orcid":false,"given":"Qian","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1643-5450","authenticated-orcid":false,"given":"Jia-qi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2366-5147","authenticated-orcid":false,"given":"Xin-bo","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7025-1022","authenticated-orcid":false,"given":"Jia-he","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6907-5866","authenticated-orcid":false,"given":"Zi-wei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3009-8702","authenticated-orcid":false,"given":"Jian-ying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3385-7997","authenticated-orcid":false,"given":"Tzu-Hua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2092-4775","authenticated-orcid":false,"given":"Wei-jiang","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2454-2168","authenticated-orcid":false,"given":"Jing","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9163-8426","authenticated-orcid":false,"given":"Qing-wen","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,27]]},"reference":[{"key":"6540_CR1","doi-asserted-by":"publisher","unstructured":"Sieper J, Rudwaleit M, Baraliakos X, Brandt J, Braun J, Burgos-Vargas R, Dougados M, Hermann KG, Landew\u00e9 R, Maksymowych W, & van der Heijde D (2009) The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Annals of the rheumatic diseases 68: Suppl 2, ii1\u2013ii44. https:\/\/doi.org\/10.1136\/ard.2008.104018","DOI":"10.1136\/ard.2008.104018"},{"key":"6540_CR2","doi-asserted-by":"publisher","unstructured":"Klavdianou K, Tsiami S, & Baraliakos X (2021) New developments in ankylosing spondylitis-status in 2021. Rheumatology (Oxford, England) 60: Suppl 6, vi29\u2013vi37. https:\/\/doi.org\/10.1093\/rheumatology\/keab523","DOI":"10.1093\/rheumatology\/keab523"},{"issue":"6","key":"6540_CR3","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1136\/ard.2009.108233","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M, van der Heijde D, Landew\u00e9 R, Listing J et al (2009) The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 68(6):777\u2013783. https:\/\/doi.org\/10.1136\/ard.2009.108233","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"6540_CR4","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s10067-020-05423-7","volume":"40","author":"D Benavent","year":"2021","unstructured":"Benavent D, Navarro-Comp\u00e1n V (2021) Understanding the paradigm of non-radiographic axial spondyloarthritis. Clin Rheumatol 40(2):501\u2013512. https:\/\/doi.org\/10.1007\/s10067-020-05423-7","journal-title":"Clin Rheumatol"},{"issue":"26","key":"6540_CR5","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1056\/NEJMra1406182","volume":"374","author":"JD Taurog","year":"2016","unstructured":"Taurog JD, Chhabra A, Colbert RA (2016) Ankylosing spondylitis and axial spondyloarthritis. N Engl J Med 374(26):2563\u20132574. https:\/\/doi.org\/10.1056\/NEJMra1406182","journal-title":"N Engl J Med"},{"issue":"4","key":"6540_CR6","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1093\/rheumatology\/ket387","volume":"53","author":"LE Dean","year":"2014","unstructured":"Dean LE, Jones GT, MacDonald AG, Downham C, Sturrock RD, Macfarlane GJ (2014) Global prevalence of ankylosing spondylitis. Rheumatology (Oxford) 53(4):650\u2013657. https:\/\/doi.org\/10.1093\/rheumatology\/ket387","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"6540_CR7","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1136\/annrheumdis-2021-221035","volume":"80","author":"V Navarro-Compan","year":"2021","unstructured":"Navarro-Compan V, Sepriano A, El-Zorkany B, van der Heijde D (2021) Axial spondyloarthritis. Ann Rheum Dis 80(12):1511\u20131521. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221035","journal-title":"Ann Rheum Dis"},{"key":"6540_CR8","doi-asserted-by":"publisher","unstructured":"Ritchlin C, & Adamopoulos IE (2021) Axial spondyloarthritis: new advances in diagnosis and management. BMJ (Clinical research ed.) 372: m4447. https:\/\/doi.org\/10.1136\/bmj.m4447","DOI":"10.1136\/bmj.m4447"},{"key":"6540_CR9","doi-asserted-by":"publisher","first-page":"382","DOI":"10.3389\/fimmu.2019.00382","volume":"10","author":"S Menegatti","year":"2019","unstructured":"Menegatti S, Bianchi E, Rogge L (2019) Anti-TNF therapy in spondyloarthritis and related diseases, impact on the immune system and prediction of treatment responses. Front Immunol 10:382. https:\/\/doi.org\/10.3389\/fimmu.2019.00382","journal-title":"Front Immunol"},{"issue":"10","key":"6540_CR10","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1002\/art.41042","volume":"71","author":"MM Ward","year":"2019","unstructured":"Ward MM, Deodhar A, Gensler LS, Dubreuil M et al (2019) 2019 Update of the American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol 71(10):1599\u20131613. https:\/\/doi.org\/10.1002\/art.41042","journal-title":"Arthritis Rheumatol"},{"key":"6540_CR11","doi-asserted-by":"publisher","unstructured":"Ortolan A, Webers C, Sepriano A, Falzon L, Baraliakos X, Landew\u00e9 RB, Ramiro S, van der Heijde D, & Nikiphorou E (2022) Efficacy and safety of non-pharmacological and non-biological interventions: a systematic literature review informing the 2022 update of the ASAS\/EULAR recommendations for the management of axial spondyloarthritis. Annals of the rheumatic diseases, ard-2022\u2013223297. Advance online publication. https:\/\/doi.org\/10.1136\/ard-2022-223297","DOI":"10.1136\/ard-2022-223297"},{"issue":"8","key":"6540_CR12","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1080\/14728222.2021.1973429","volume":"25","author":"B Cherqaoui","year":"2021","unstructured":"Cherqaoui B, Araujo LM, Glatigny S, Breban M (2021) Axial spondyloarthritis: emerging drug targets. Expert Opin Ther Targets 25(8):633\u2013644. https:\/\/doi.org\/10.1080\/14728222.2021.1973429","journal-title":"Expert Opin Ther Targets"},{"issue":"4","key":"6540_CR13","first-page":"579","volume":"35","author":"PP Sfikakis","year":"2017","unstructured":"Sfikakis PP, Bournia VK, Sidiropoulos P, Boumpas DT, Drosos AA, Kitas GD, Konstantonis G, Liossis SN, Manoussakis MN, Sakkas L, Tektonidou M, Tzioufas AG, Vlachoyiannopoulos PG, Kani C, Paterakis P, Litsa P, Vassilopoulos D (2017) Biologic treatment for rheumatic disease: real-world big data analysis from the Greek country-wide prescription database. Clin Exp Rheumatol 35(4):579\u2013585","journal-title":"Clin Exp Rheumatol"},{"key":"6540_CR14","doi-asserted-by":"publisher","unstructured":"Prieto-Pe\u00f1a D, Dasgupta B (2021) Biologic agents and small-molecule inhibitors in systemic autoimmune conditions: an update. Pol Arch Intern Med 131(2):171\u2013181. https:\/\/doi.org\/10.20452\/pamw.15438","DOI":"10.20452\/pamw.15438"},{"key":"6540_CR15","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.jbusres.2021.04.070","volume":"133","author":"N Donthu","year":"2021","unstructured":"Donthu N, Kumar S, Mukherjee D, Pandey N, Lim WM (2021) How to conduct a bibliometric analysis: an overview and guidelines. J Bus Res 133:285\u2013296. https:\/\/doi.org\/10.1016\/j.jbusres.2021.04.070","journal-title":"J Bus Res"},{"key":"6540_CR16","doi-asserted-by":"publisher","unstructured":"Liu X, Zhao S, Tan L, Tan Y, Wang Y, Ye Z, Hou C, Xu Y, Liu S, Wang G (2022) Frontier and hot topics in electrochemiluminescence sensing technology based on CiteSpace bibliometric analysis. Biosens Bioelectron 201:113932. https:\/\/doi.org\/10.1016\/j.bios.2021.113932","DOI":"10.1016\/j.bios.2021.113932"},{"issue":"1","key":"6540_CR17","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1136\/ard-2022-223298","volume":"82","author":"C Webers","year":"2023","unstructured":"Webers C, Ortolan A, Sepriano A, Falzon L, Baraliakos X, Landew\u00e9 RBM, Ramiro S, van der Heijde D, Nikiphorou E (2023) Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis. Ann Rheum Dis 82(1):130\u2013141. https:\/\/doi.org\/10.1136\/ard-2022-223298","journal-title":"Ann Rheum Dis"},{"key":"6540_CR18","doi-asserted-by":"publisher","unstructured":"Miao L, Zhang J, Zhang Z, Wang S, Tang F, Teng M, Li Y (2022) A bibliometric and knowledge-map analysis of CAR-T cells from 2009 to 2021. Front Immunol 13:840956. https:\/\/doi.org\/10.3389\/fimmu.2022.840956","DOI":"10.3389\/fimmu.2022.840956"},{"issue":"12","key":"6540_CR19","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1007\/s00296-022-05138-9","volume":"42","author":"J Chen","year":"2022","unstructured":"Chen J, He Q, Jiang B, Song W, Wu Z, Yang J, Huang Z, Yu X, Luo J, Tao Q (2022) Research on primary Sj\u00f6gren\u2019s syndrome in 2004\u20132021: a Web of Science-based cross-sectional bibliometric analysis. Rheumatol Int 42(12):2221\u20132229. https:\/\/doi.org\/10.1007\/s00296-022-05138-9","journal-title":"Rheumatol Int"},{"key":"6540_CR20","doi-asserted-by":"publisher","unstructured":"Zhang J, Song L, Jia J, Tian W, Lai R, Zhang Z, Li J, Ju J, & Xu H (2022) Knowledge mapping of necroptosis from 2012 to 2021: a bibliometric analysis. Frontiers in immunology 13: 917155. https:\/\/doi.org\/10.3389\/fimmu.2022.917155","DOI":"10.3389\/fimmu.2022.917155"},{"issue":"6","key":"6540_CR21","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","volume":"76","author":"D Van der Heijde","year":"2017","unstructured":"Van der Heijde D, Ramiro S, Landewe R, Baraliakos X et al (2017) 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis 76(6):978\u2013991. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210770","journal-title":"Ann Rheum Dis"},{"issue":"9313","key":"6540_CR22","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/s0140-6736(02)08215-6","volume":"359","author":"J Braun","year":"2002","unstructured":"Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, Gromnica-Ihle E, Kellner H, Krause A, Schneider M, S\u00f6rensen H, Zeidler H, Thriene W, Sieper J (2002) Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet (London, England) 359(9313):1187\u20131193. https:\/\/doi.org\/10.1016\/s0140-6736(02)08215-6","journal-title":"Lancet (London, England)"},{"issue":"26","key":"6540_CR23","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","volume":"373","author":"Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, Deodhar A, Porter B, Martin R, Andersson M, Mpofu S, Richards HB, MEASURE 1 Study Group, & MEASURE 2 Study Group","year":"2015","unstructured":"Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, Deodhar A, Porter B, Martin R, Andersson M, Mpofu S, Richards HB, MEASURE 1 Study Group, & MEASURE 2 Study Group (2015) Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med 373(26):2534\u20132548. https:\/\/doi.org\/10.1056\/NEJMoa1505066","journal-title":"N Engl J Med"},{"issue":"2","key":"6540_CR24","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1002\/art.20852","volume":"52","author":"Van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, Braun J, & Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group","year":"2005","unstructured":"Van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, Braun J, & Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group (2005) Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 52(2):582\u2013591. https:\/\/doi.org\/10.1002\/art.20852","journal-title":"Arthritis Rheum"},{"issue":"6","key":"6540_CR25","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1136\/ard.2011.151027","volume":"70","author":"J Braun","year":"2011","unstructured":"Braun J, van den Berg R, Baraliakos X, Boehm H et al (2011) 2010 update of the ASAS\/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 70(6):896\u2013904. https:\/\/doi.org\/10.1136\/ard.2011.151027","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"6540_CR26","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.1002\/art.11325","volume":"48","author":"Davis JC, Van Der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, Kivitz A, Fleischmann R, Inman R, Tsuji W, & Enbrel Ankylosing Spondylitis Study Group","year":"2003","unstructured":"Davis JC, Van Der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, Kivitz A, Fleischmann R, Inman R, Tsuji W, & Enbrel Ankylosing Spondylitis Study Group (2003) Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 48(11):3230\u20133236. https:\/\/doi.org\/10.1002\/art.11325","journal-title":"Arthritis Rheum"},{"issue":"7","key":"6540_CR27","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1002\/art.21913","volume":"54","author":"Van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J, Dougados M, Reveille JD, Wong RL, Kupper H, Davis JC. Jr, & ATLAS Study Group","year":"2006","unstructured":"Van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J, Dougados M, Reveille JD, Wong RL, Kupper H, Davis JC. Jr, & ATLAS Study Group (2006) Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 54(7):2136\u20132146. https:\/\/doi.org\/10.1002\/art.21913","journal-title":"Arthritis Rheum"},{"issue":"6","key":"6540_CR28","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1136\/annrheumdis-2012-201766","volume":"72","author":"J Sieper","year":"2013","unstructured":"Sieper J, van der Heijde D, Dougados M, Mease PJ, Maksymowych WP, Brown MA, Arora V, Pangan AL (2013) Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis 72(6):815\u2013822. https:\/\/doi.org\/10.1136\/annrheumdis-2012-201766","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"6540_CR29","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1136\/annrheumdis-2013-204231","volume":"73","author":"R Landew\u00e9","year":"2014","unstructured":"Landew\u00e9 R, Braun J, Deodhar A, Dougados M, Maksymowych WP, Mease PJ, Reveille JD, Rudwaleit M, van der Heijde D, Stach C, Hoepken B, Fichtner A, Coteur G, de Longueville M, Sieper J (2014) Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. Ann Rheum Dis 73(1):39\u201347. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204231","journal-title":"Ann Rheum Dis"},{"issue":"10089","key":"6540_CR30","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0140-6736(16)31591-4","volume":"390","author":"J Sieper","year":"2017","unstructured":"Sieper J, Poddubnyy D (2017) Axial spondyloarthritis. Lancet 390(10089):73\u201384. https:\/\/doi.org\/10.1016\/S0140-6736(16)31591-4","journal-title":"Lancet"},{"issue":"9","key":"6540_CR31","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1136\/ard.2008.096073","volume":"68","author":"U Kiltz","year":"2009","unstructured":"Kiltz U, van der Heijde D, Mielants H, Feldtkeller E, Braun J, group PEpi, (2009) ASAS\/EULAR recommendations for the management of ankylosing spondylitis: the patient version. Ann Rheum Dis 68(9):1381\u20131386. https:\/\/doi.org\/10.1136\/ard.2008.096073","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"6540_CR32","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1136\/annrheumdis-2013-204248","volume":"73","author":"D Poddubnyy","year":"2014","unstructured":"Poddubnyy D, Hermann KG, Callhoff J, Listing J, Sieper J (2014) Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS). Ann Rheum Dis 73(5):817\u2013823. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204248","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"6540_CR33","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1136\/annrheumdis-2016-210322","volume":"76","author":"D Van der Heijde","year":"2017","unstructured":"Van der Heijde D, Deodhar A, Wei JC, Drescher E, Fleishaker D, Hendrikx T, Li D, Menon S, Kanik KS (2017) Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study. Ann Rheum Dis 76(8):1340\u20131347. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210322","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"6540_CR34","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1136\/annrheumdis-2015-207963","volume":"75","author":"CJ Edwards","year":"2016","unstructured":"Edwards CJ, Blanco FJ, Crowley J, Birbara CA, Jaworski J, Aelion J, Stevens RM, Vessey A, Zhan X, Bird P (2016) Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3). Ann Rheum Dis 75(6):1065\u20131073. https:\/\/doi.org\/10.1136\/annrheumdis-2015-207963","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"6540_CR35","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1136\/annrheumdis-2020-219601","volume":"80","author":"A Deodhar","year":"2021","unstructured":"Deodhar A, Sliwinska-Stanczyk P, Xu H, Baraliakos X, Gensler LS, Fleishaker D, Wu WL, J, Menon S, Wang C, Dina O, Fallon L, Kanik KS, & van der Heijde D, (2021) Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study. Ann Rheum Dis 80(8):1004\u20131013. https:\/\/doi.org\/10.1136\/annrheumdis-2020-219601","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"6540_CR36","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.3899\/jrheum.201088","volume":"48","author":"PC Taylor","year":"2021","unstructured":"Taylor PC, van der Heijde D, Landew\u00e9 R, McCue S, Cheng S, Boonen A (2021) A phase III randomized study of apremilast, an oral phosphodiesterase 4 inhibitor, for active ankylosing spondylitis. J Rheumatol 48(8):1259\u20131267. https:\/\/doi.org\/10.3899\/jrheum.201088","journal-title":"J Rheumatol"},{"issue":"7","key":"6540_CR37","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1080\/1744666X.2021.1925541","volume":"17","author":"S Keeling","year":"2021","unstructured":"Keeling S, Maksymowych WP (2021) JAK inhibitors, psoriatic arthritis, and axial spondyloarthritis: a critical review of clinical trials. Expert Rev Clin Immunol 17(7):701\u2013715. https:\/\/doi.org\/10.1080\/1744666X.2021.1925541","journal-title":"Expert Rev Clin Immunol"},{"key":"6540_CR38","doi-asserted-by":"publisher","unstructured":"Van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27(4):361\u2013368. https:\/\/doi.org\/10.1002\/art.1780270401","DOI":"10.1002\/art.1780270401"},{"issue":"9","key":"6540_CR39","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1007\/s00256-022-04018-4","volume":"51","author":"T Diekhoff","year":"2022","unstructured":"Diekhoff T, Lambert R, Hermann KG (2022) MRI in axial spondyloarthritis: understanding an \u2018ASAS-positive MRI\u2019 and the ASAS classification criteria. Skeletal Radiol 51(9):1721\u20131730. https:\/\/doi.org\/10.1007\/s00256-022-04018-4","journal-title":"Skeletal Radiol"},{"issue":"11","key":"6540_CR40","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1136\/annrheumdis-2015-208642","volume":"75","author":"RG Lambert","year":"2016","unstructured":"Lambert RG, Bakker PA, van der Heijde D, Weber U et al (2016) Defining active sacroiliitis on MRI for classification of axial spondyloarthritis: update by the ASAS MRI working group. Ann Rheum Dis 75(11):1958\u20131963. https:\/\/doi.org\/10.1136\/annrheumdis-2015-208642","journal-title":"Ann Rheum Dis"},{"key":"6540_CR41","doi-asserted-by":"publisher","unstructured":"Protopopov M, Proft F, Wichuk S, Machado PM, Lambert RG, Weber U, Juhl Pedersen S, \u00d8stergaard M, Sieper J, Rudwaleit M, Baraliakos X, Maksymowych WP, & Poddubnyy D (2022) Comparing MRI and conventional radiography for the detection of structural changes indicative of axial spondyloarthritis in the ASAS cohort. Rheumatology (Oxford, England) keac432. Advance online publication. https:\/\/doi.org\/10.1093\/rheumatology\/keac432","DOI":"10.1093\/rheumatology\/keac432"},{"issue":"2","key":"6540_CR42","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1002\/acr.24459","volume":"74","author":"A Sepriano","year":"2022","unstructured":"Sepriano A, Ramiro S, van der Heijde D, Dougados M, Claudepierre P, Feydy A, Reijnierse M, Loeuille D, Landew\u00e9 R (2022) Imaging outcomes for axial spondyloarthritis and sensitivity to change: a five-year analysis of the DESIR cohort. Arthritis Care Res 74(2):251\u2013258. https:\/\/doi.org\/10.1002\/acr.24459","journal-title":"Arthritis Care Res"},{"key":"6540_CR43","doi-asserted-by":"publisher","unstructured":"Liu D, Lin C, Liu B, Qi J, Wen H, Tu L, Wei Q, Kong Q, Xie Y, & Gu J (2022) Quantification of fat metaplasia in the sacroiliac joints of patients with axial spondyloarthritis by chemical shift-encoded MRI: a diagnostic trial. Frontiers in immunology 12: 811672. https:\/\/doi.org\/10.3389\/fimmu.2021.811672","DOI":"10.3389\/fimmu.2021.811672"},{"issue":"6","key":"6540_CR44","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1093\/rheumatology\/keab755","volume":"61","author":"M Wetterslev","year":"2022","unstructured":"Wetterslev M, Georgiadis S, S\u00f8rensen IJ, Pedersen SJ et al (2022) Tapering of TNF inhibitors in axial spondyloarthritis in routine care - 2-year clinical and MRI outcomes and predictors of successful tapering. Rheumatology (Oxford) 61(6):2398\u20132412. https:\/\/doi.org\/10.1093\/rheumatology\/keab755","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"6540_CR45","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s40261-020-00886-7","volume":"40","author":"Baraliakos X, \u00d8stergaard M, Gensler LS, Poddubnyy D, Lee EY, Kiltz U, Martin R, Sawata H, Readie A, Porter B, & SURPASS Study Group","year":"2020","unstructured":"Baraliakos X, \u00d8stergaard M, Gensler LS, Poddubnyy D, Lee EY, Kiltz U, Martin R, Sawata H, Readie A, Porter B, & SURPASS Study Group (2020) Comparison of the effects of secukinumab and adalimumab biosimilar on radiographic progression in patients with ankylosing spondylitis: design of a randomized, phase IIIb study (SURPASS). Clin Drug Investig 40(3):269\u2013278. https:\/\/doi.org\/10.1007\/s40261-020-00886-7","journal-title":"Clin Drug Investig"},{"key":"6540_CR46","doi-asserted-by":"publisher","unstructured":"Scrivo R, Castellani C, Mancuso S, Sciarra G, Giardina F, Bevignani G, Ceccarelli F, Spinelli FR, Alessandri C, Di Franco M, Riccieri V, Priori R, & Conti F (2022) Effectiveness of non-medical switch from adalimumab bio-originator to SB5 biosimilar and from ABP501 adalimumab biosimilar to SB5 biosimilar in patients with chronic inflammatory arthropathies: a monocentric observational study. Clinical and experimental rheumatology. Advance online publication. https:\/\/doi.org\/10.55563\/clinexprheumatol\/bf00j9","DOI":"10.55563\/clinexprheumatol\/bf00j9"},{"key":"6540_CR47","doi-asserted-by":"publisher","first-page":"175628482110314","DOI":"10.1177\/17562848211031420","volume":"14","author":"B Barberio","year":"2021","unstructured":"Barberio B, Cingolani L, Canova C, Barbieri G, Sablich R, Urbano MT, Bertani L, Costa F, Bodini G, Demarzo MG, Ferronato A, Buda A, Melatti P, Massimi D, Savarino EV, Zingone F (2021) A propensity score-weighted comparison between adalimumab originator and its biosimilars, ABP501 and SB5, in inflammatory bowel disease: a multicenter Italian study. Ther Adv Gastroenterol 14:17562848211031420. https:\/\/doi.org\/10.1177\/17562848211031420","journal-title":"Ther Adv Gastroenterol"},{"key":"6540_CR48","doi-asserted-by":"publisher","unstructured":"Wang R, Dasgupta A, Ward MM (2022) Predicting probability of response to tumor necrosis factor inhibitors for individual patients with ankylosing spondylitis. JAMA Netw Open 5(3): e222312. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.2312","DOI":"10.1001\/jamanetworkopen.2022.2312"},{"issue":"1","key":"6540_CR49","doi-asserted-by":"publisher","first-page":"20299","DOI":"10.1038\/s41598-020-75352-7","volume":"10","author":"S Lee","year":"2020","unstructured":"Lee S, Eun Y, Kim H, Cha HS, Koh EM, Lee J (2020) Machine learning to predict early TNF inhibitor users in patients with ankylosing spondylitis. Sci Rep 10(1):20299. https:\/\/doi.org\/10.1038\/s41598-020-75352-7","journal-title":"Sci Rep"},{"issue":"1","key":"6540_CR50","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1186\/s13075-021-02635-3","volume":"23","author":"S Lee","year":"2021","unstructured":"Lee S, Kang S, Eun Y, Won HH, Kim H, Lee J, Koh EM, Cha HS (2021) Machine learning-based prediction model for responses of bDMARDs in patients with rheumatoid arthritis and ankylosing spondylitis. Arthritis Res Ther 23(1):254. https:\/\/doi.org\/10.1186\/s13075-021-02635-3","journal-title":"Arthritis Res Ther"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-023-06540-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-023-06540-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-023-06540-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T07:10:05Z","timestamp":1689232205000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-023-06540-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,27]]},"references-count":50,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["6540"],"URL":"https:\/\/doi.org\/10.1007\/s10067-023-06540-9","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,27]]},"assertion":[{"value":"7 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare that they have no conflict of interest. Figure B was created by Figdraw (), accessed on 23 December 2022.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}